ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually providing an update on the use of the “at the market” equity of its offering plan.
As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement an “at-the market” equity offering system under which Acasti may well issue as well as sell from time to time its everyday shares having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January 27, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 huge number of. The ATM Shares ended up being offered at prevailing market prices averaging US$1.0747 per share. No securities were offered in the facilities of the TSXV or maybe, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with the services of theirs. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will deliver the Company with more freedom in its continuous review process to enjoy and evaluate strategic options.
About Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically concentrated on the research, development and commercialization of prescribed drugs using OM3 greasy acids delivered both as free fatty acids as well as bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have extensive clinical proof of safety and efficacy in lowering triglycerides in individuals with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of that press release which are not statements of historical or current truth constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking claims include known and unknown risks, uncertainties, along with other unknown variables that could cause the particular results of Acasti to be materially different from historical results and even from any future outcomes expressed or perhaps implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, people are actually urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other related expressions to be uncertain and forward-looking. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak just as of the particular date of this press release. Forward-looking assertions in this press release include, but are not confined to, information or statements about Acasti’s strategy, succeeding operations as well as its review of strategic options.
The forward looking claims found in this specific press release are expressly qualified in their entirety by this cautionary declaration, the “Special Note Regarding Forward-Looking Statements” area in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor section of Acasti’s site at www.acastipharma.com. All forward-looking statements in this press release are made as of the day of this press release.
ACST Stock – Acasti doesn’t undertake to redesign some such forward looking statements whether as a result of info which is new, future events or otherwise, except as called for by law. The forward-looking assertions contained herein are also subject typically to risks and assumptions and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, including Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the usage